Not exact matches
US - based pharmaceutical company Gilead Sciences entered the chimeric antigen receptor (CAR) T -
cell therapy business through its acquisition of Kite Pharma,
and Australian biopharma company CSL Behring acquired US - based Calimmune, a company that
develops clinical - stage
gene therapy solutions.
Two of 10 children treated with
gene therapy for SCID in a French trial
develop leukemia, researchers announced in 2002,
and it is discovered that the virus had inserted
genes in several unexpected places around the genome, leading the
cells to become cancerous.
For his part, Collins, who has led NIH since 2009
and been kept on by the Trump administration, pointed to an array of promising NIH activities, including the development of new technologies to provide insights into human brain circuitry
and function through the Brain Research through Advancing Innovative Neuroethologies (BRAIN initiative)
and the use of the
gene - editing tool CRISPR - Cas9 to correct mutations
and clear the way to
develop and test a «curative
therapy» for the first molecular disease: sickle
cell disease.
Researchers at the Center for
Cell and Gene Therapy at Baylor College of Medicine, Texas Children's Hospital
and Houston Methodist have
developed an alternative treatment in which virus - specific
cells protect patients against severe, drug - resistant viral infections.
«Researchers ID cancer
gene - drug combinations ripe for precision medicine: Yeast, human
cells and bioinformatics help
develop one - two punch approach to personalized cancer
therapy.»
In a step toward accelerating the production of new
gene therapies, scientists report in ACS Nano that they have
developed remote - controlled, needle - like nanospears capable of piercing membrane walls
and delivering DNA into selected
cells.
Dr. Levine directs the Clinical
Cell and Vaccine Production Facility (CVPF), which develops, manufactures, and tests novel cell and gene therapies in clinical trials at Penn and collaborating instituti
Cell and Vaccine Production Facility (CVPF), which
develops, manufactures,
and tests novel
cell and gene therapies in clinical trials at Penn and collaborating instituti
cell and gene therapies in clinical trials at Penn
and collaborating institutions.
Boston Children's Hospital has offered non-exclusive licenses to for - profit entities on a patent
developed by Orkin's laboratory regarding BCL11A, a genetic switch regulating hemoglobin production that is expected to form the basis of clinical trials for
gene therapy and gene editing for sickle
cell disease
and thalassemia.
In recent years, scientists have grown new retinal
cells from stem
cells and shown progress in
developing an effective
gene therapy.
Amongst others, Dr. Sonntag's work has contributed to
developing a
cell therapy for Parkinson's disease (PD),
and to understanding a role of dysregulated
gene and miRNA expression networks in PD
and schizophrenia, or dopaminergic
and adrenergic receptors in hedonic
and impulsive behavior.
Intellia is
developing human
gene and cell therapies for both ex vivo
and in vivo applications using CRISPR - Cas9
gene editing technology.
A physician with a longstanding interest in
gene therapy, Dr. High was formerly a Professor at the Perelman School of Medicine of the University of Pennsylvania, an Investigator of the Howard Hughes Medical Institute,
and the Founding Director of the Center for Cellular
and Molecular Therapeutics at The Children's Hospital of Philadelphia, a Center focused on
developing novel
cell and gene - based
therapies for genetic disease.
The company is
developing CAR T -
cell immunotherapies for multiple myeloma, prostate
and other cancer types, as well as
gene therapies for orphan diseases.
While the vast majority of research in this field is focused on
developing stem
cell,
gene and tissue engineering
therapies, these approaches have not yet delivered on their promise despite nearly two decades of research.
It's about co-funding industrial facilities for
developing and producing
gene and cell therapies,
and to build up a new economic sector.
The CRISPR - Cas technology can be used to screen for druggable targets
and to
develop gene and cell therapies for unmet medical needs.
But efforts to
develop adoptive T
cell therapies for solid tumors have hit upon a number of challenges; the only
gene therapies to show significant benefit for patients have been in liquid tumors — forms of leukemia
and lymphoma.
Supported by: Hear from leading expert Dr David DiGiusto, Stanford University School of Medicine, USA, as he shares his extensive experience in
developing and optimizing manufacturing processes for
cell and gene therapy products including:
Don't miss the chance to make new contacts, connect with current clients,
develop your
cell therapy, regenerative medicine
and gene therapy business.
American Society of
Gene and Cell Therapy Annual Meeting Speaker: Olivia Kelly, Ph.D., Senior Director,
Cell Biology Presentation:
Developing a
Cell Therapy Combination Product for Diabetes Date / Time: May 16, 8:30 AM EDT Location: Hilton Chicago, Chicago
Oisín Biotechnology — a startup with initial funding from SENS Research Foundation, the Methuselah Foundation,
and others — is close behind them, having
developed a form of
gene therapy that — in animals at least — also destroys these
cells, using an approach that is less inherently likely to destroy healthy
cells along with senescent ones.
Gene and cell therapies have made important medical advances over the past three decade,
developing technologies
and testing novel
therapies in multiple human clinical trials of many diseases.